Skip Nav Destination
Issues
1 August 2011
-
Cover Image
Cover Image
Modification of the glycolipid ligands for natural killer T (NKT) cells might be an efficient approach to improve their stimulatory activity or to shift the proportional release of Th1 and Th2 cytokines. The chemical modified iGb3 analogue, 4‴-dh-iGb3, made by introducing a hydroxyl group at C4 of iGb3 and removing the 4″′ hydroxyl group of the terminal galactose, could increase the stability of the CD1d/antigen/TCR ternary complex and IFN-γ signaling ofNKTcells, and thus stimulate more IFN-γ production by NKT cells. 4‴-dh-iGb3-loaded dendritic cells significantly inhibit growth of subcutaneous melanoma and suppress lung metastasis in C57BL/6 mice. The 4‴-dh-iGb3-loaded dendritic cell vaccine may serve as a potent new NKT-based therapy against tumors. For details, see article by Zhou and colleagues on page 1375. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Spotlight on Clinical Response
Therapeutic Discovery
Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Chun-Te Chen; Hirohito Yamaguchi; Hong-Jen Lee; Yi Du; Heng-Huan Lee; Weiya Xia; Wen-Hsuan Yu; Jennifer L. Hsu; Chia-Jui Yen; Hui-Lung Sun; Yan Wang; Edward T.H. Yeh; Gabriel N. Hortobagyi; Mien-Chie Hung
High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion
Laura Muinelo-Romay; Eva Colas; Jorge Barbazan; Lorena Alonso-Alconada; Marta Alonso-Nocelo; Marta Bouso; Teresa Curiel; Juan Cueva; Urbano Anido; Jeronimo Forteza; Antonio Gil-Moreno; Jaume Reventos; Rafael Lopez-Lopez; Miguel Abal
Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors
Wenle Xia; Zuguo Liu; Rongrong Zong; Leihua Liu; Sumin Zhao; Sarah S. Bacus; Yubin Mao; Jia He; Julia D. Wulfkuhle; Emanuel F. Petricoin, III; Takuya Osada; Xiao-Yi Yang; Zachary C. Hartman; Timothy M. Clay; Kimberly L. Blackwell; Herbert K. Lyerly; Neil L. Spector
Preclinical Development
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Shripad V. Bhagwat; Prafulla C. Gokhale; Andrew P. Crew; Andy Cooke; Yan Yao; Christine Mantis; Jennifer Kahler; Jennifer Workman; Mark Bittner; Lorina Dudkin; David M. Epstein; Neil W. Gibson; Robert Wild; Lee D. Arnold; Peter J. Houghton; Jonathan A. Pachter
Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Aleksandra Bielen; Lara Perryman; Gary M. Box; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Alexa Jury; Sergey Popov; Sharon Gowan; Sebastien Jeay; Florence I. Raynaud; Francesco Hofmann; Darren Hargrave; Suzanne A. Eccles; Chris Jones
Peloruside- and Laulimalide-Resistant Human Ovarian Carcinoma Cells Have βI-Tubulin Mutations and Altered Expression of βII- and βIII-Tubulin Isotypes
Arun Kanakkanthara; Anja Wilmes; Aurora O'Brate; Daniel Escuin; Ariane Chan; Ada Gjyrezi; Janet Crawford; Pisana Rawson; Bronwyn Kivell; Peter T. Northcote; Ernest Hamel; Paraskevi Giannakakou; John H. Miller
Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Daniele G. Soares; Miriana S. Machado; Céline J. Rocca; Virginie Poindessous; Djamila Ouaret; Alain Sarasin; Carlos M. Galmarini; João A.P. Henriques; Alexandre E. Escargueil; Annette K. Larsen
Molecular Medicine in Practice
Rationally Designed Treatment for Solid Tumors with MAPK Pathway Activation: A Phase I Study of Paclitaxel and Bortezomib Using an Adaptive Dose-Finding Approach
Janice M. Mehnert; Antoinette R. Tan; Rebecca Moss; Elizabeth Poplin; Mark N. Stein; Mika Sovak; Kelly Levinson; Hongxia Lin; Michael Kane; Murugesan Gounder; Yong Lin; Weichung Joe Shih; Eileen White; Eric H. Rubin; Vassiliki Karantza
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.